ORICELL THERAPEUTICS
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.
ORICELL THERAPEUTICS
Social Links:
Industry:
Health Care Pharmaceutical Product Research
Founded:
2015-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.oricell.com
Total Employee:
101+
Status:
Active
Contact:
8621-68868119
Total Funding:
165.49 M USD
Investors List
C&D Emerging Investment
C&D Emerging Investment investment in Series B - Oricell Therapeutics
J One Capital
J One Capital investment in Series B - Oricell Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Oricell Therapeutics
Shanghai Sci-Tech Innovation Center Capital
Shanghai Sci-Tech Innovation Center Capital investment in Series B - Oricell Therapeutics
Boquan Equity Investment Management
Boquan Equity Investment Management investment in Series B - Oricell Therapeutics
Quan Capital
Quan Capital investment in Series B - Oricell Therapeutics
Suzhou Fund
Suzhou Fund investment in Series B - Oricell Therapeutics
Shanghai Pudong Science and Technology Investment
Shanghai Pudong Science and Technology Investment investment in Series A - Oricell Therapeutics
Zhangjiang Science & Technology Investment Corporation
Zhangjiang Science & Technology Investment Corporation investment in Series A - Oricell Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series A - Oricell Therapeutics
Official Site Inspections
http://www.oricell.com Semrush global rank: 5.82 M Semrush visits lastest month: 1.43 K
- Host name: 47.100.248.106
- IP address: 47.100.248.106
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Oricell Therapeutics"
About Us - oricell.com
Founded in 2015, Oricell Therapeutics is dedicated to pioneering innovative and clinically valuable immunotherapies focusing on a wide range of indications. Committed to cost-effective and enduring cellular drugs, we strive to address …See details»
Oricell Therapeutics - Crunchbase Company Profile
Organization. Oricell Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy …See details»
关于我们 - oricell.com
何晓文 Ph.D. 联合创始人 / CSO. 拥有超过20年在分子生物学和免疫学领域的专业知识和创新研究经验，何博士一直深耕肿瘤免疫微环境的研究，并致力于通过CAR-T细胞相关的发育和代谢研究，开创性地推动他和团队为Oricell创建了一 …See details»
原启生物 - 成为创新驱动的全球领先，肿瘤免疫治疗新 …
上海，2024年8月20日 —— 原启生物（Oricell Therapeutics）宣布，任命Kenneth C. Anderson 教授和Shaji Kumar 教授加入公司科学顾问委员会（Scientific Advisory Board, SAB）。See details»
Oricell Therapeutics - LinkedIn
Oricell Therapeutics | 2,426 followers on LinkedIn. Committed to Developing Novel Immunotherapies | Founded in 2015, Oricell Therapeutics aims to develop drugs with good …See details»
OriCell Therapeutics Raises Over $120 Million in Series B Financing …
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- OriCell Therapeutics (Shanghai) Co., Ltd. ("OriCell" or "the Company") has announced the completion of Series B financing totaling over US$120 …See details»
Oricell Announces FDA Clearance of IND Application for OriCAR …
Jan 29, 2024 Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's …See details»
Oricell Closes $45M Series B1 Financing to Expand ... - Markets …
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ('Oricell' or 'the Company'), a China-based innovative pharmaceutical compan... Menu icon A vertical stack of …See details»
Oricell Therapeutics - Committed to Developing Novel …
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact. Shanghai, China—August 10, 2023, in a groundbreaking development, Oricell Therapeutics …See details»
Oricell’s GPRC5D-Targeted CAR Cleared for US Evaluation in …
Feb 20, 2024 The FDA has cleared Oricell’s investigational new drug (IND) application of OriCAR-017, allowing the company to initiate clinical development for patients with …See details»
Oricell Closes $45M Series B1 Financing to Expand Development …
SHANGHAI, Feb. 28, 2023 /PRNewswire/ — Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), a China-based innovative pharmaceutical company committed to the …See details»
Oricell Announces FDA Clearance of IND Application for OriCAR …
Jan 29, 2024 Oricell is a clinical-stage biotechnology company, dedicated to developing innovative cell therapie s t o address unmet medical needs in oncology and immunology …See details»
Oricell Closes $45M Series B1 Financing to Expand Development …
Feb 28, 2023 Oricell Chairman and CEO Helen Yang said, "We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further …See details»
Oricell Presented Long-term Follow-up Data of OriCAR-017 in …
Jun 5, 2024 Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I …See details»
Oricell Closes $45M Series B1 Financing to Expand Development …
SHANGHAI, Feb. 28th, 2023 -- Oricell Therapeutics Co., Ltd (“Oricell” or “the Company”), a China-based innovative pharmaceutical company committed to the development of tumor …See details»
OriCell Therapeutics Raises Over $120 Million in Series B Financing
Jul 31, 2022 SHANGHAI, August 1, 2022 -- OriCell Therapeutics (Shanghai) Co., Ltd. ("OriCell" or "the Company”) has announced the completion of Series B financing totaling over US$120 …See details»
FDA Clears Oricell to Begin CAR T Trial in Multiple Myeloma
Jan 31, 2024 Oricell is also developing a GPC3-targeted CAR T-cell therapy, Ori-C101, for hepatocellular carcinoma and is conducting a Phase I clinical trial of the product with …See details»
Oricell Obtained FDA IND Clearance of OriCAR-017, a Novel …
Jan 30, 2024 Oricell is a clinical-stage biotechnology company, dedicated to developing innovative cell therapies to address unmet medical needs in oncology and immunology around …See details»
Our Pipeline - oricell.com
The first CAR-T product developed by Oricell for the treatment of advanced hepatocellular carcinoma, has received positive data from its exploratory clinical study and was presented at …See details»
OriCell Therapeutics - VentureRadar
Oricell Therapeutics is a biopharmaceutical company committed to developing tumor cellular immunotherapeutics through its technology platforms. The company has applied for over 100 …See details»